Tolerogenic dendritic cells generated with tofacitinib ameliorate experimental autoimmune encephalomyelitis through modulation of Th17/Treg balance

Journal of Immunology Research

Volumn 2016, Issue , 2016, Pages

  Zhou, Yan ^a   Leng, Xiao ^b   Luo, Shasha ^b   Su, Zhiwei ^b   Luo, Xingyan ^b   Guo, Huijie ^b   Mo, Chunfen ^b   Zou, Qiang ^b   Liu, Yang ^b   Wang, Yantang ^b  

^a SICHUAN UNIVERSITY   (China)

^b CHENGDU MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MYELIN OLIGODENDROCYTE GLYCOPROTEIN; TOFACITINIB; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ADOPTIVE CELL THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; BONE MARROW DERIVED DENDRITIC CELL; CELL THERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DENDRITIC CELL; DISEASE ACTIVITY; DISEASE SEVERITY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; IMMUNE RESPONSE; IMMUNOMODULATION; MOUSE; MULTIPLE SCLEROSIS; NEUROMODULATION; NONHUMAN; REGULATORY T LYMPHOCYTE; SPLEEN CELL; TH1 CELL; TH17 CELL; TOLEROGENIC DENDRITIC CELL; ADOPTIVE IMMUNOTHERAPY; ANIMAL; C57BL MOUSE; CD4 LYMPHOCYTE COUNT; CELL CULTURE; CYTOLOGY; DISEASE MODEL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; TRANSPLANTATION;

ANIMALS; CD4 LYMPHOCYTE COUNT; CELLS, CULTURED; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; IMMUNE TOLERANCE; IMMUNOTHERAPY, ADOPTIVE; MICE; MICE, INBRED C57BL; MULTIPLE SCLEROSIS; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH17 CELLS;

EID: 85008893460     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2016/5021537     Document Type: Article

References (39)

1. H. Torres-Aguilar, M. Blank, L. J. Jara, and Y. Shoenfeld, "Tolerogenic dendritic cells in autoimmune diseases: crucial players in induction and prevention of autoimmunity, " Autoimmunity Reviews, vol. 10, no. 1, pp. 8-17, 2010.
2. C. Reis E Sousa, "Dendritic cells in a mature age, " Nature Reviews Immunology, vol. 6, no. 6, pp. 476-483, 2006.
3. S. Rutella, S. Danese, andG. Leone, "Tolerogenicdendritic cells: cytokine modulation comes of age, " Blood, vol. 108, no. 5, pp. 1435-1440, 2006.
4. R. M. Steinman, D. Hawiger, and M. C. Nussenzweig, "Tolerogenic dendritic cells, " Annual Review of Immunology, vol. 21, pp. 685-711, 2003.
5. S. Price, "Experimental arthritis: therapeutic effects of tolerogenic dendritic cells, " Nature Reviews Rheumatology, vol. 6, no. 12, p. 674, 2010.
6. C. Llanos, J. P. Mackern-Oberti, F. Vega, S. H. Jacobelli, and A. M. Kalergis, "Tolerogenic dendritic cells as a therapy for treating lupus, " Clinical Immunology, vol. 148, no. 2, pp. 237-245, 2013.
7. J. N. Stoop, R. A. Harry, A. Von Delwig, J. D. Isaacs, J. H. Robinson, and C. M. U. Hilkens, "Therapeutic effect of tolerogenic dendritic cells in established collagen-induced arthritis is associated with a reduction in Th17 responses, " Arthritis and Rheumatology, vol. 62, no. 12, pp. 3656-3665, 2010.
8. D. Rach-Regué, L. Grau-López, M. Naranjo-Gómez et al. , "Stable antigen-specific T-cell hyporesponsiveness induced by tolerogenic dendritic cells from multiple sclerosis patients, " European Journal of Immunology, vol. 42, no. 3, pp. 771-782, 2012.
9. Y. Ren, Y. Yang, J. Yang, R. Xie, and H. Fan, "Tolerogenic dendritic cells modified by tacrolimus suppress CD4+ T-cell proliferation and inhibit collagen-induced arthritis in mice, " International Immunopharmacology, vol. 21, no. 1, pp. 247-254, 2014.
10. L. Adorini, N. Giarratana, and G. Penna, "Pharmacological induction of tolerogenic dendritic cells and regulatory T cells, " Seminars in Immunology, vol. 16, no. 2, pp. 127-134, 2004.
11. E. B. Lee, R. Fleischmann, S. Hall et al. , "Tofacitinib versus methotrexate in rheumatoid arthritis, "TheNew England Journal of Medicine, vol. 370, no. 25, pp. 2377-2386, 2014.
12. J. H. Coombs, B. J. Bloom, F. C. Breedveld et al. , "Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690, 550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial, " Annals of the Rheumatic Diseases, vol. 69, no. 2, pp. 413-416, 2010.
13. R. F. van Vollenhoven, "Small molecular compounds in development for rheumatoid arthritis, " Current Opinion in Rheumatology, vol. 25, no. 3, pp. 391-397, 2013.
14. H. M. Baldwin, T. Ito-Ihara, J. D. Isaacs, and C. M. U. Hilkens, "Tumour necrosis factor alpha blockade impairs dendritic cell survival and function in rheumatoid arthritis, " Annals of the Rheumatic Diseases, vol. 69, no. 6, pp. 1200-1207, 2010.
15. A. Rivas-Caicedo, G. Soldevila, T. I. Fortoul, A. Castell-Rodríguez, L. Flores-Romo, and E. A. García-Zepeda, "Jak3 is involved in dendritic cell maturation and CCR7-dependent migration, " PLoS ONE, vol. 4, no. 9, article e7066, 2009.
16. S. Kubo, K. Yamaoka, M. Kondo et al. , "The JAKinhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells, " Annals of the Rheumatic Diseases, vol. 73, no. 12, pp. 2192-2198, 2014.
17. K. Maeshima, K. Yamaoka, S. Kubo et al. , "The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-and interleukin-17 production by human CD4+ T cells, " Arthritis and Rheumatism, vol. 64, no. 6, pp. 1790-1798, 2012.
18. A. S. Farias, G. S. Spagnol, P. Bordeaux-Rego et al. , "Vitamin D3 induces IDO+ tolerogenic DCs and enhances treg, reducing the severity of EAE, " CNSNeuroscience and Therapeutics, vol. 19, no. 4, pp. 269-277, 2013.
19. M. Comabella, X. Montalban, C. Münz, and J. D. Lünemann, "Targeting dendritic cells to treat multiple sclerosis, " Nature Reviews Neurology, vol. 6, no. 9, pp. 499-507, 2010.
20. K. Inaba, M. Inaba, N. Romani et al. , "Generation of large numbers of dendritic cells frommouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor, " Journal of Experimental Medicine, vol. 176, no. 6, pp. 1693-1702, 1992.
21. I. M. Stromnes and J. M. Goverman, "Active induction of experimental allergic encephalomyelitis, " Nature Protocols, vol. 1, no. 4, pp. 1810-1819, 2006.
22. G. Zandman-Goddard, S. S. Pierangeli, S. Gertel, andM. Blank, "Tolerogenic dendritic cells specific for 2-glycoprotein-IDomain-I, attenuate experimental antiphospholipid syndrome, " Journal of Autoimmunity, vol. 54, pp. 72-80, 2014.
23. S. W. Way and B. Popko, "Harnessing the integrated stress response for the treatment of multiple sclerosis, " The Lancet Neurology, vol. 15, no. 4, pp. 434-443, 2016.
24. J. Goverman, "Autoimmune T cell responses in the central nervous system, " Nature Reviews Immunology, vol. 9, no. 6, pp. 393-407, 2009.
25. Z.-X. Xie, H.-L. Zhang, X.-J. Wu, J. Zhu, D.-H. Ma, and T. Jin, "Role of the immunogenic and tolerogenic subsets of dendritic cells inmultiple sclerosis, "Mediators of Inflammation, vol. 2015, Article ID 513295, 2015.
26. N. Anandasabapathy, G. D. Victora, M. Meredith et al. , "Flt3L controls the development of radiosensitive dendritic cells in the meninges and choroid plexus of the steady-state mouse brain, " Journal of ExperimentalMedicine, vol. 208, no. 18, pp. 1695-1705, 2011.
27. G. B. Ferreira, C. A. Gysemans, J. Demengeot et al. , "1, 25-Dihydroxyvitamin D3 promotes tolerogenic dendritic cells with functional migratory properties in NODMice, " The Journal of Immunology, vol. 192, no. 9, pp. 4210-4220, 2014.
28. E. Segura, M. Touzot, A. Bohineust et al. , "Human inflammatory dendritic cells induce Th17 cell differentiation, " Immunity, vol. 38, no. 2, pp. 336-348, 2013.
29. H. Tanaka, C. E. Demeure, M. Rubio, G. Delespesse, and M. Sarfati, "Human monocyte-derived dendritic cells induce naive T cell differentiation into T helper cell type 2 (Th2) orTh1/Th2 effectors. Role of stimulator/responder ratio, " The Journal of Experimental Medicine, vol. 192, no. 3, pp. 405-412, 2000.
30. V. Rothhammer, S. Heink, F. Petermann et al. , "Th17 lymphocytes traffic to the central nervous system independently of 4 integrin expression during EAE, " The Journal of Experimental Medicine, vol. 208, no. 12, pp. 2465-2476, 2011.
31. Y. Sonobe, H. Li, S. Jin et al. , "Midkine inhibits inducible regulatory T cell differentiation by suppressing the development of tolerogenic dendritic cells, " Journal of Immunology, vol. 188, no. 6, pp. 2602-2611, 2012.
32. M. Fransson, E. Piras, J. Burman et al. , "CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery, " Journal of Neuroinflammation, vol. 9, article 112, 2012.
33. H. Yoshida, A. Kimura, T. Fukaya et al. , "Low dose CP-690, 550 (tofacitinib), a pan-JAKinhibitor, accelerates the onset of experimental autoimmune encephalomyelitis by potentiating Th17 differentiation, " Biochemical and Biophysical Research Communications, vol. 418, no. 2, pp. 234-240, 2012.
34. K. Ghoreschi, M. I. Jesson, X. Li et al. , "Modulation of innate and adaptive immune responses by tofacitinib (CP-690, 550), " Journal of Immunology, vol. 186, no. 7, pp. 4234-4243, 2011.
35. M. J. Mansilla, R. Contreras-Cardone, J. Navarro-Barriuso et al. , "Cryopreserved vitamin D3-tolerogenic dendritic cells pulsed with autoantigens as a potential therapy for multiple sclerosis patients, " Journal of Neuroinflammation, vol. 13, no. 1, article 113, 2016.
36. C. C. Gross, H. Jonuleit, and H. Wiendl, "Fulfilling the dream: tolerogenic dendritic cells to treat multiple sclerosis, " European Journal of Immunology, vol. 42, no. 3, pp. 569-572, 2012.
37. J. B. Rothbard, X. Zhao, O. Sharpe et al. , "Chaperone activity of B-crystallin is responsible for its incorrect assignment as an autoantigen in multiple sclerosis, " The Journal of Immunology, vol. 186, no. 7, pp. 4263-4268, 2011.
38. B. Ayoglu, N. Mitsios, I. Kockum et al. , "Anoctamin 2 identified as an autoimmune target in multiple sclerosis, " Proceedings of the National Academy of Sciences of the United States, vol. 113, no. 8, pp. 2188-2193, 2016.
39. A. Brickshawana, S. R. Hinson, M. F. Romero et al. , "Investigation of the KIR4. 1 potassium channel as a putative antigen in patients with multiple sclerosis: A comparative study, " The Lancet Neurology, vol. 13, no. 8, pp. 795-806, 2014.